N-[2-butyl-4-methyl-1-oxo-2-(3-oxobutyl)-3H-inden-5-yl]acetamide | 429683-16-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: N-[2-butyl-4-methyl-1-oxo-2-(3-oxobutyl)-3H-inden-5-yl]acetamide
• CAS: 429683-16-9
• 化学式: C₂₀H₂₇NO₃
• 分子量: 329.439
• InChiKey: RPAMTULAVACRDM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  24
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  63.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-[2-butyl-4-methyl-1-oxo-2-(3-oxobutyl)-3H-inden-5-yl]acetamide 在 四氢吡咯 、 盐酸 、 copper(l) iodide 、 二苯并-18-冠醚-6 、 溴 、 potassium acetate 、 碳酸氢钠 、 nitrosonium tetrafluoroborate 、 溶剂黄146 作用下， 以 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 生成 (S)-9a-butyl-6-(trifluoromethyl)-8,9,9a,10-tetrahydroindeno[2,1-e]indazol-7(3H)-one
  参考文献：
  名称：

  Estrogen receptor β-subtype selective tetrahydrofluorenones: Use of a fused pyrazole as a phenol bioisostere

  摘要：

  Synthesis of a series of fused pyrazole tetrahydrofluorenone analogs which are potent, ERP subtype selective ligands is described. Analogs possessing subnanomolar ERP binding, greater than 100-fold ER beta-selectivity, and oral bioavailability are reported. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.05.036
• 作为产物：
  描述：

  N1-(1-氧-2,3-二氢-1H-茚-5-基)乙酰胺 在 palladium on activated charcoal 氢氧化钾 、 N-溴代丁二酰亚胺(NBS) 、 tetrakis(triphenylphosphine)palladium dichloride 、 氢气 、 sodium methylate 、 三苯基膦 、 lithium chloride 作用下， 以 甲醇 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 N-[2-butyl-4-methyl-1-oxo-2-(3-oxobutyl)-3H-inden-5-yl]acetamide
  参考文献：
  名称：

  Estrogen receptor β-subtype selective tetrahydrofluorenones: Use of a fused pyrazole as a phenol bioisostere

  摘要：

  Synthesis of a series of fused pyrazole tetrahydrofluorenone analogs which are potent, ERP subtype selective ligands is described. Analogs possessing subnanomolar ERP binding, greater than 100-fold ER beta-selectivity, and oral bioavailability are reported. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.05.036

文献信息

• ESTROGEN RECEPTOR MODULATORS
  申请人：Merck & Co., Inc.

  公开号：EP1339683A2

  公开（公告）日：2003-09-03
• EP1339683A4
  申请人：——

  公开号：EP1339683A4

  公开（公告）日：2005-07-27
• [EN] ESTROGEN RECEPTOR MODULATORS<br/>[FR] MODULATEURS DE RECEPTEURS D'OESTROGENES
  申请人：MERCK & CO INC

  公开号：WO2002041835A2

  公开（公告）日：2002-05-30

  The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restinosis, gynacomastia, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer, in particular of the breast, uterus and prostate.
• Estrogen receptor β-subtype selective tetrahydrofluorenones: Use of a fused pyrazole as a phenol bioisostere
  作者：R.R. Wilkening、R.W. Ratcliffe、A.K. Fried、D. Meng、W. Sun、L. Colwell、S. Lambert、M. Greenlee、S. Nilsson、A. Thorsell、M. Mojena、C. Tudela、K. Frisch、W. Chan、E.T. Birzin、S.P. Rohrer、M.L. Hammond

  DOI：10.1016/j.bmcl.2006.05.036

  日期：2006.8

  Synthesis of a series of fused pyrazole tetrahydrofluorenone analogs which are potent, ERP subtype selective ligands is described. Analogs possessing subnanomolar ERP binding, greater than 100-fold ER beta-selectivity, and oral bioavailability are reported. (c) 2006 Elsevier Ltd. All rights reserved.